FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912696157> ?p ?o ?g. }

• W2912696157 endingPage "S202" @default.
• W2912696157 startingPage "S202" @default.
• W2912696157 abstract "IntroductionAn ex vivo photodepletion method has been developed to produce ATIR101 (Kiadis Pharma), a donor lymphocyte infusion administered after haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) to aid immune reconstitution. ATIR101 is depleted of alloreactive T cells; early administration after T-cell-depleted haplo-HSCT has the potential to reduce serious complications resulting from delayed immune reconstitution. The safety and efficacy of ATIR101 are presented in a pooled analysis of 2 phase II trials: CR-AIR-007, NCT01794299; CR-AIR-008, NCT02500550.MethodsA pooled analysis of 2 trials with similar protocols in 37 adult patients (1-year follow-up in n=34; data cut-off June 1, 2018). N=32 patients received a single dose of ATIR101 (2.0 × 106 cells/kg); n=5 discontinued after HSCT and did not receive ATIR101 (death n=2; graft failure n=1; batch rejection n=2). Of the 37 patients, 65% had acute myeloid leukemia, 27% had acute lymphoblastic leukemia, and 8% had myelodysplastic syndromes; patients had intermediate (57%) and high (43%) disease risk index. All underwent myeloablative conditioning followed by a CD34+-selected stem cell graft from a haploidentical family donor. ATIR101, prepared from the same donor, was given at a median of 28 days post HSCT without prophylactic immunosuppression. Outcomes were compared with a historic control group of 35 patients treated with a T-cell-depleted CD34+ selected haplo-HSCT without ATIR101 (CR-AIR-006, NCT02188290).ResultsThirty-six patients engrafted, with neutrophil and platelet engraftment at a median (range) of 14 days (8–34) and 12 days (7–35) post HSCT, respectively. Non-relapse mortality (NRM) was 33% and relapse-related mortality was 8% compared with 66% and 15%, respectively, in the control group (Table). The overall survival (OS) was 58% vs 20% in the control group (Fig. A). Total chronic GVHD was 3% vs 11%, chronic severe GVHD was 0% vs 9%, and acute GVHD grade III–IV was 5% (all grade III) vs 6%, respectively. Survival analysis without grade III/IV acute GVHD, chronic GVHD requiring systemic treatment, or relapse (GRFS) showed significant separation for the pooled cohort vs control group (P=0.01; Fig. B); 1-year GRFS rates for both groups were 53% and 20%, respectively.ConclusionOS was ∼3-fold higher in the pooled cohort than in the control group. Disease relapse was limited and NRM in the pooled cohort was half that of the control group. ATIR101 was well tolerated. Results suggest that ATIR101 does not increase GVHD beyond the levels reported with a T-cell-depleted CD34+ selected HSCT alone. GRFS was >2.5-fold higher than in the control group; rates seem higher than reported in studies using post-transplant cyclophosphamide after T-cell-replete HSCT (Solh 2017, McCurdy 2017). A phase III trial of ATIR101 after T-cell-depleted haplo-HSCT vs PTCy after T-cell-replete haplo-HSCT is ongoing." @default.
• W2912696157 created "2019-02-21" @default.
• W2912696157 creator A5000244387 @default.
• W2912696157 creator A5037134717 @default.
• W2912696157 creator A5040551037 @default.
• W2912696157 creator A5041128935 @default.
• W2912696157 creator A5049107543 @default.
• W2912696157 creator A5050692336 @default.
• W2912696157 creator A5052348906 @default.
• W2912696157 creator A5079198423 @default.
• W2912696157 creator A5081650438 @default.
• W2912696157 creator A5082157943 @default.
• W2912696157 creator A5086668079 @default.
• W2912696157 date "2019-03-01" @default.
• W2912696157 modified "2023-10-03" @default.
• W2912696157 title "A Single Dose of Donor Lymphocytes Depleted of Alloreactive T Cells (ATIR101) after Haploidentical HSCT Is Well-Tolerated and Efficacious: Pooled Analysis of Two Phase II Studies" @default.
• W2912696157 doi "https://doi.org/10.1016/j.bbmt.2018.12.274" @default.
• W2912696157 hasPublicationYear "2019" @default.
• W2912696157 type Work @default.
• W2912696157 sameAs 2912696157 @default.
• W2912696157 citedByCount "1" @default.
• W2912696157 countsByYear W29126961572019 @default.
• W2912696157 crossrefType "journal-article" @default.
• W2912696157 hasAuthorship W2912696157A5000244387 @default.
• W2912696157 hasAuthorship W2912696157A5037134717 @default.
• W2912696157 hasAuthorship W2912696157A5040551037 @default.
• W2912696157 hasAuthorship W2912696157A5041128935 @default.
• W2912696157 hasAuthorship W2912696157A5049107543 @default.
• W2912696157 hasAuthorship W2912696157A5050692336 @default.
• W2912696157 hasAuthorship W2912696157A5052348906 @default.
• W2912696157 hasAuthorship W2912696157A5079198423 @default.
• W2912696157 hasAuthorship W2912696157A5081650438 @default.
• W2912696157 hasAuthorship W2912696157A5082157943 @default.
• W2912696157 hasAuthorship W2912696157A5086668079 @default.
• W2912696157 hasBestOaLocation W29126961571 @default.
• W2912696157 hasConcept C10205521 @default.
• W2912696157 hasConcept C126322002 @default.
• W2912696157 hasConcept C203014093 @default.
• W2912696157 hasConcept C2776090121 @default.
• W2912696157 hasConcept C2776863199 @default.
• W2912696157 hasConcept C2777408962 @default.
• W2912696157 hasConcept C2778461978 @default.
• W2912696157 hasConcept C2778729363 @default.
• W2912696157 hasConcept C2780252810 @default.
• W2912696157 hasConcept C28328180 @default.
• W2912696157 hasConcept C2911091166 @default.
• W2912696157 hasConcept C54355233 @default.
• W2912696157 hasConcept C71924100 @default.
• W2912696157 hasConcept C86803240 @default.
• W2912696157 hasConcept C8891405 @default.
• W2912696157 hasConcept C90924648 @default.
• W2912696157 hasConceptScore W2912696157C10205521 @default.
• W2912696157 hasConceptScore W2912696157C126322002 @default.
• W2912696157 hasConceptScore W2912696157C203014093 @default.
• W2912696157 hasConceptScore W2912696157C2776090121 @default.
• W2912696157 hasConceptScore W2912696157C2776863199 @default.
• W2912696157 hasConceptScore W2912696157C2777408962 @default.
• W2912696157 hasConceptScore W2912696157C2778461978 @default.
• W2912696157 hasConceptScore W2912696157C2778729363 @default.
• W2912696157 hasConceptScore W2912696157C2780252810 @default.
• W2912696157 hasConceptScore W2912696157C28328180 @default.
• W2912696157 hasConceptScore W2912696157C2911091166 @default.
• W2912696157 hasConceptScore W2912696157C54355233 @default.
• W2912696157 hasConceptScore W2912696157C71924100 @default.
• W2912696157 hasConceptScore W2912696157C86803240 @default.
• W2912696157 hasConceptScore W2912696157C8891405 @default.
• W2912696157 hasConceptScore W2912696157C90924648 @default.
• W2912696157 hasIssue "3" @default.
• W2912696157 hasLocation W29126961571 @default.
• W2912696157 hasOpenAccess W2912696157 @default.
• W2912696157 hasPrimaryLocation W29126961571 @default.
• W2912696157 hasRelatedWork W2161603182 @default.
• W2912696157 hasRelatedWork W2350274480 @default.
• W2912696157 hasRelatedWork W2351420399 @default.
• W2912696157 hasRelatedWork W2366793411 @default.
• W2912696157 hasRelatedWork W2393383561 @default.
• W2912696157 hasRelatedWork W2394313917 @default.
• W2912696157 hasRelatedWork W2981957994 @default.
• W2912696157 hasRelatedWork W3039046190 @default.
• W2912696157 hasRelatedWork W4303685354 @default.
• W2912696157 hasRelatedWork W4303945795 @default.
• W2912696157 hasVolume "25" @default.
• W2912696157 isParatext "false" @default.
• W2912696157 isRetracted "false" @default.
• W2912696157 magId "2912696157" @default.
• W2912696157 workType "article" @default.